The “Band” (Jörn Schattenberg, Stephen Harrison, Louise Campbell and Roger Green) gets back together with no other guests to talk NASH Clinical Trials, improving screen fail rates, finding more patients and, generally, what has changed since Jörn co-authored his 2020 article on the NASH Clinical Trial Graveyard.
The “Band” (Jörn Schattenberg, Stephen Harrison, Louise Campbell and Roger Green) gets back together with no other guests to talk NASH Clinical Trials, improving screen fail rates, finding more patients and, generally, what has changed since Jörn co-authored his 2020 article on the NASH Clinical Trial Graveyard.
The “Band” (Jörn Schattenberg, Stephen Harrison, Louise Campbell and Roger Green) gets back together with no other guests to talk NASH Clinical Trials, improving screen fail rates, finding more patients and, generally, what has changed since Jörn co-authored his 2020 article on the NASH Clinical Trial Graveyard.
Jörn Schattenberg joins Stephen Harrison, Louise Campbell and Roger Green to talk NASH Clinical Trials, improving screen fail rates, and finding more patients.
This episode discusses the unique role NASH cirrhosis studies can play in clinical trial design, particularly in the transition from biopsy as gold standard to a post-biopsy world. Stephen Harrison starts this conversation by discussing why we focus on NASH cirrhosis and goes on to review the recent presentation of results from the REVERSE study on obeticholic acid. Jörn Schattenberg and Mazen Noureddin add their perspectives to the conversation.
Co-authors Michelle Long and Mazen Noureddin join Louise Campbell and Roger Green to discuss their recent publication on Best Practice in lean NASH. This conversation focuses on the challenges of alcohol screening when assessing a patient for Fatty Liver disease.
Co-authors Michelle Long and Mazen Noureddin join Louise Campbell and Roger Green to discuss their recent publication on Best Practice in lean NASH. This conversation focuses on why early diagnosis is so important when dealing with Lean NASH.
Co-authors Michelle Long and Mazen Noureddin join Louise Campbell and Roger Green to discuss their recent publication on Best Practice in lean NASH. This conversation focuses on the elegant one-page diagnostic algorithm they recommend for diagnosing Lean NASH in “normal” BMI patients with signs of liver disease.
Co-authors Michelle Long and Mazen Noureddin join Louise Campbell and Roger Green to discuss their recent publication on Best Practice in lean NASH. This conversation focuses on how this article came to be and the key steps in researching and writing it.
Co-authors Michelle Long and Mazen Noureddin join Louise Campbell and Roger Green to discuss their recent Clinical Practice Update in Gastroenterology titled “Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.”
In this conversation from September 2021, Anthony Villiotti of NASH kNOWledge joins Louise Campbell and Roger Green to discuss his “biggest story of the summer:” two publications, on demonstrating that NASH prevalence and incidence may be far higher than we believe and another demonstrating how limited public knowledge about NASH is today.
Ian Rowe’s decision curve model does an excellent job of modeling the success rate and cost effectiveness of modeling early NASH diagnosis. However, as Louise Campbell points out, simply getting the patient diagnosed does not mean therapeutic success, which has implications for the early diagnosis model and broader patient management issues.
Ian Rowe, Louise Campbell and Roger Green discuss two issues in NASH patient management: the number of patients that are told they have Fatty Livers not to worry about treating it, and the general challenges in treating patients whose NASH is part of a constellation of metabolic diseases.
Professor Ian Rowe and Louise Campbell share opinions and insights on the need to improve diagnosis of clinically relevant fibrosis and how some of these issues are reflected in the decision curve model Ian has built with Richard Parker. discusses the issues that led him and his colleague Richard Parker to create a model to determine the most cost effective approach to early diagnosis of clinically significant fibrosis, along with a description of the model they built.
Professor Ian Rowe discusses the issues that led him and his colleague Richard Parker to create a model to determine the most cost effective approach to early diagnosis of clinically significant fibrosis, along with a description of the model they built.
Ian Rowe joins the Surfers to share a poster he co-authored at this year’s EASL International Liver Congress. The poster shares a decision model Professor Rowe developed to analysis the cost effectiveness of five different strategies for early NASH diagnosis.
From May of this year, INCBCN 2022 co-chair Jeff Lazarus joins the Surfers (including co-chair Jörn Schattenberg) to discuss the recent conference in Barcelona. This conversation asks what “patient empowerment” means to Fatty Liver stakeholders.
From March of this year, Quentin Anstee joins the Surfers to discuss his recent paper (first co-author Helen Brunt, many co-authors) discussing how inconsistency in ballooned hepatocyte reads have led to NASH clinical trial failures that were artifacts of poor methodology.
From last November, Global Liver Institute Founder, President and CEO Donna Cryer and her fellow patient and patient advocate Terri Milton join the Surfers to discuss the ground-breaking NASH Patient-Focused Drug Development meeting held with FDA.
From February of this year, Stephen Harrison and Mazen Noureddin join Jörn Schattenberg, Louise Campbell and Roger Green to discuss the formation of the new NAIL-NIT consortium, led by Stephen and Mazen. This conversation focuses on the specific challenges inherent in the NAS scores.
From November 2021, the Surfers and guests Manal Abdelmalek and Ian Rowe discuss highlights from the previous week’s AASLD 2021 meeting. This episode focuses on the question of how to “put a big, fat dent” in Fatty Liver disease. One answer: Transition more quickly to NITs.
From September 2021, Stephen Harrison and Jörn Schattenberg lead the Surfers on a deep dive into the fibrosis section of the recent Paris NASH conference. The conversation focuses on fibrosis and the role of stellate cells in fibrogenesis.
In this episode from October 2021, Scott Friedman joins the Surfers to reprise high points from his Paris NASH presentation the previous month. Key topics include precision medicine, fibrosis, and the history and all-important role of the stellate cell.
Our 2nd anniversary look in the Vault starts with Jörn Schattenberg’s first episode as a featured guest, a 2020 episode reviewing his article on why NASH drug trials fail. One key focus was the proper design and use of Phase 2 trials.
This week, Surfing the NASH Tsunami celebrates its 2nd Buzzsprout Anniversary by crossing the 80,000 download barrier and more! Jörn Schattenberg and Roger Green discuss some of NASH Tsunami’s highlights over that time.
Antaros Medical co-founder and Chief Scientific Officer Lars Johansson joined the Surfers to explore opportunities to improve scientific insight surrounding NASH cirrhosis and cirrhosis patient care. This conversation sums up much of the previous discussion, with the conclusion that as diagnostic technologies and drugs in development improve, the need to communicate better with patients remains pivotal for successful therapies.
Antaros Medical co-founder and Chief Scientific Officer Lars Johansson joined the Surfers to explore opportunities to improve scientific insight and patient care surrounding NASH cirrhosis. This conversation focuses on a “pincer movement” in the technology necessary to support cirrhosis patients: low-end technology to foster better patient communication and education, and high-end medical technology to diagnose, stage and treat the disease faster and more accurately.
Antaros Medical co-founder and Chief Scientific Officer Lars Johansson joined the Surfers to explore opportunities to improve scientific insight and patient care surrounding NASH cirrhosis. This conversation asks where we will find the next major breakthrough in treating cirrhosis patients.
Antaros Medical co-founder and Chief Scientific Officer Lars Johansson joined the Surfers to explore opportunities to improve scientific insight and patient care surrounding NASH cirrhosis. This conversation focuses on the ability of current medications to cause fibrosis regression in patients with NASH cirrhosis.
Antaros Medical co-founder and Chief Scientific Officer Lars Johansson joined the Surfers to explore opportunities to improve scientific insight and patient care surrounding NASH Cirrhosis Screening and Diagnostic Tests.
Antaros Medical co-founder and Chief Scientific Officer Lars Johansson joined the Surfers to explore opportunities to improve scientific insight and patient care surrounding NASH cirrhosis.
Stephen Harrison leads the rest of the Surfers (Jörn Schattenberg, Louise Campbell and Roger Green), through a discussion of Intercept Pharmaceuticals’ July 7 press release on re-analysis of the REGENERATE trial evaluating obeticholic acid (OCA) for treating of NASH fibrosis. This conversation asks (and attempts to answer) whether the REGENERATE reanalysis is likely to succeed in getting the drug approved.
Stephen Harrison leads the rest of the Surfers (Jörn Schattenberg, Louise Campbell and Roger Green), through a discussion of Intercept Pharmaceuticals’ July 7 press release on re-analysis of the REGENERATE trial evaluating obeticholic acid (OCA) for treating of NASH fibrosis. This conversation focuses on…
Stephen Harrison leads the rest of the Surfers (Jörn Schattenberg, Louise Campbell and Roger Green), through a discussion of Intercept Pharmaceuticals’ July 7 press release on re-analysis of the REGENERATE trial evaluating obeticholic acid (OCA) for treating of NASH fibrosis. This conversation focuses on safety and tolerability issues in this analysis. This is important because most observers believe it was the risk:benefit tradeoff analysis that led to the Complete Response Letter in 2020.
Stephen Harrison leads the rest of the Surfers (Jörn Schattenberg, Louise Campbell and Roger Green), through a discussion of Intercept Pharmaceuticals’ July 7 press release on re-analysis of the REGENERATE trial evaluating obeticholic acid (OCA) for treating of NASH fibrosis. This conversation focuses on the meaning of the efficacy results in this trial and what they imply for patient therapy.
Stephen Harrison leads the rest of the Surfers (Jörn Schattenberg, Louise Campbell and Roger Green), through a discussion of Intercept Pharmaceuticals’ July 7 press release on re-analysis of the REGENERATE trial evaluating obeticholic acid (OCA) for treating of NASH fibrosis. This conversation focuses on its basic efficacy results.
The Core Four (Stephen Harrison, Jörn Schattenberg, Louise Campbell, and Roger Green) review Intercept Pharmaceuticals’s recent press release on the new REGENERATE findings and ask whether these results are strong enough for OCA to gain approval in NASH fibrosis.
Scott Friedman, Neil Henderson and Rachel Zayas join the Surfers to discuss a groundbreaking session from #ILC2022 discussing advances in what Liver Science can tell us about fibrosis. This conversation focuses on Roger Green’s final question, which asks for tangible changes that will ensue over the next 1-5 years as impact of advances in the liver science research processes and findings discussed in this episode.
Scott Friedman, Neil Henderson and Rachel Zayas join the Surfers to discuss a groundbreaking session from #ILC2022 discussing advances in what Liver Science can tell us about fibrosis. This conversation focuses on…
Scott Friedman, Neil Henderson and Rachel Zayas join the Surfers to discuss a groundbreaking session from #ILC2022 discussing advances in what Liver Science can tell us about fibrosis. This conversation focuses on…
Scott Friedman, Neil Henderson and Rachel Zayas join the Surfers to discuss a groundbreaking session from #ILC2022 discussing advances in what Liver Science can tell us about fibrosis. This conversation focuses on two abstracts that explore the stellate cell dynamics in the creation and resolution of fibrotic scars. Both of these rely on the kinds of single cell analyses that lie at the heart of much of Neil Henderson’s research.
Last month, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (ILC 2022.) On Thursday afternoon, Scott Friedman chaired an abstract session discussing advances in the basic science of researching and understanding mechanisms surrounding fibrosis and stellate cells.
Scott Friedman, Neil Henderson and Rachel Zayas join the Surfers to discuss a groundbreaking session from #ILC2022 discussing advances in what Liver Science can tell us about fibrosis.
The group discusses implications of the semaglutide cirrhosis late-breaker and shares what they anticipate might be different one year from now.
Stephen Harrison leads the regular Surfers, Mazen Noureddin and Michelle Long through a discussion of Phase 1 results for pemvidutide, Altimune’s dual GLP-1/glucagon agonist for obesity (and presumably NASH), based on his presentation at ILC2022.
After Stephen Harrison shares key elements from two of his resmetirom presentations at #ILC2022, Jörn Schattenberg, Mazen Noureddin and Michelle Long share thoughts and questions about the presentation. After this, Jörn Schattenberg shares key points from his presentation of an assessment of accuracy of FIB-4 in 2,000 biopsy-confirmed patients in the resmetirom trials.
Stephen Harrison leads a panel including the regular Surfers, Mazen Noureddin and Michelle Long through key elements of his presentation of the Phase 3 MAESTRO NAFLD-1 study at #ILC2022. He also shares information about an analysis of cirrhotic patients in the open-label cohort of the study.
Michelle Long and Mazen Noureddin join the Surfers (including Stephen Harrison) for a wrap-up of the major stories of #ILC2022. Much of the episode focuses on NASH Drug Development, with side conversations about the value and challenges of relying on FIB-4 or, even worse, ALT in patient screening and diagnosis.
Louise Campbell and Robert Mitchell-Thain discuss the world of NAFLD patients both in interacting with clinicians and in living their daily lives
From our #ILC2022 wrap-up episodes, Louise Campbell and Robert Mitchell-Thain discuss the role of NAFLD nurses as communicators delivering pivotal messages to patients, particularly when those messages involve social or person stigma.
Mazen Noureddin and Ian Rowe join Louise Campbell and Jörn Schattenberg to discuss an important discussion about the roles different NITs will play in the future of NASH diagnosis, treatment and monitoring. Then Louise talks with PBC Foundation CEO Robert Mitchell-Thain about
Last week, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022,) the first major hepatology Congress to be held in person since the start of the pandemic (smaller, but very valuable, meetings like NASH-TAG, LiverCONNECT and Paris NASH have taken place with an in-person component, but the International Liver Congress and The Liver Meeting have not).
Last week, roughly 5,000 liver community stakeholders gathered in London for the 2022 International Liver Congress (#ILC2022,) the first major hepatology Congress to be held in person since the start of the pandemic (smaller, but very valuable, meetings like NASH-TAG, LiverCONNECT and Paris NASH have taken place with an in-person component, but the International Liver Congress and The Liver Meeting have not).
MichelleLong and Zobair Younossi join the Surfers to discuss the first three days of #OLC2022. This conversation centers on patient motivation through test results and coaching and why adding FIB-4 or a different first-line NAFLD test to quality measures is so important.
Michelle Long and Zobair Younossi join the Surfers to discuss the first three days of #ILC2022.
Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green identify some of what they believe will be key papers at #ILC2022. This conversation focuses largely on OS025 Non-invasive fibrosis scores as prognostic biomarkers of liver events, cardiovascular events and all-cause mortality in people with obesity and/or type 2 diabetes in the UK: a longitudinal cohort study.
Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green identify some of what they believe will be key papers at 3ILC2022. This conversation focuses on the impact of NAFLD on quality of life.
Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green identify some of what they believe will be key papers at 3ILC2022. This conversation focuses on FRI100, which assessees the value of different tests in a real-world setting, and OS044, which explores general and disease-specific Quality-of-Life scores for patients with different levels of Fatty Liver disease against a control group with no disease.
Stephen Harrison, Jörn Schattenberg, Louise Campbell and Roger Green identify some of what they believe will be key papers at 3ILC2022. This conversation focuses on OS 097, which uses LITMUS Metacohort Data to identify the biomarkers that predict each of the four element of the NASH score best and FRI094, a study that evaluates the cost of community-based NAFLD screening for Type 2 Diabetes patients.
Jörn Schattenberg, Stephen Harrison, Louise Campbell and Roger Green discuss some of the most striking and important Fatty Liver-related abstracts to be presented at next week’s #ILC2022 meeting in London. Some key drug development papers are embargoed, but there were plenty of important works on NITs, quality-of-life and general patient issues for the group to discuss.
Highlights from the last section of the NASH-Day Wrap-up Panel at Global Liver Institute #NASHDay 2022. GLI NASH Programs Director Jeff McIntyre asks the panelists what #StopNASHNow means to them. Jörn Schattenberg, Louise Campbell and Roger Green provide the answers.
Highlights from the first section of the NASH-Day Wrap-up Panel at Global Liver Institute #NASHDay 2022. GLI NASH Programs Director Jeff McIntyre asks the questions and Jörn Schattenberg, Louise Campbell and Roger Green provide the answers.
Jörn Schattenberg, Louise Campbell, Stephen Harrison and Roger Green share “SurfingNASH predictions” of the most important events that will take place between the 5th and 6th International NASH Days.
Jörn Schattenberg and Louise Campbell discuss their excitement about NASH Community Collaboration around issues ranging from clinical trial design to care pathways to the role of patients.
Jörn Schattenberg, Louise Campbell and Roger Green react to Stephen Harrison’s description of major advances in Phase 3 clinical trial design (in Episode 28.1)
